← hubDrugs

4 sources

← All substances
🔗 MergedComparePsychonautWikiTripSitPharmacologyDrugCentral

Collated from PsychonautWiki, TripSit, Pharmacology, DrugCentral. Where sources differ (e.g. dosing), Compare shows them side by side.

Sections

Also known as Tianeptine, Stablon, Coaxil, TatinolPW

A Tricyclic antidepressant, that has quite unique pharmacological properties than others in its class. Such as the possible indirect action on NMDA/AMPA and a full agonist at the μ-opioid receptor. While abuse of this substance is uncommon, it has been shown in a few countries.TS

Addiction potentialPW
mildly addictive
ToxicityPW
large therapeutic index and margin of safety
TolerancePW
full tolerance with prolonged use; half after 3 - 7 days; baseline after 1 - 2 weeks
Cross-tolerancePW
trycyclic antidepressants, opioids

Oral

Route dataPsychonautWiki

ThresholdLightCommonStrongHeavy
3 mg6–12 mg12–35 mg35–100 mg100 mg+
0125 mg
LightCommonStrongHeavy
Onset30–60 minutes
Come-up15–30 minutes
Peak60–90 minutes
Offset30–60 minutes
Total2–3 hours
OnsetCome-upPeakOffset

🧬 Receptor activityDC

TargetActionAffinitySource
Mu-type opioid receptor (OPRM1)6.417 KiDRUGCENTRAL
‹ PrevPage 1 / 11–1 of 1Next ›

Mechanism of actionPH

Recent studies suggest that tianeptine acts as a full agonist at the mu-type opioid receptor (MOR),. The mu opioid receptors are currently being studied as effective targets for antidepressant therapies. It is believed that the clinical effects of tianeptine are owed to its modulation of these receptors. In addition to its actions on the opioid receptor, previous studies have owed its action to its effect on the serotonin receptor,, dopamine (D2/3) receptors, and glutamate receptors,, as discussed below: Tianeptine has challenged the monoaminergic hypothesis of depression, as well as the widely supported monoaminergic mechanisms whereby the action of most known antidepressants have been explained. Specifically, this drug is thought to persistently alter glutamate receptor bursting of the hippocampal CA3 commissural associational synapse. Current research suggests that tianeptine produces its antidepressant effects through the modulation of glutamate receptor activity (for example, AMPA receptors and NMDA receptors) and affect the release of brain-derived neurotrophic factor (BDNF), which impacts neural plasticity. More recent studies by support the role of tianeptine in the modulation of glutaminergic activity in the amygdala, the emotional region of the brain associated with memories. Tianeptine reduces the hypothalamic-pituitary-adrenal response to stress, and thus prevents stress-related behavioral issues. In rodents, the stress of acute restraint increases extracellular levels of glutamate in the basolateral amygdala an effect that was inhibited by tianeptine. Interestingly, the SSRI fluoxetine increased extracellular glutamate levels in the basolateral amygdala regardless of stress conditions. These data demonstrate that the mechanism of action of tianeptine is distinct from SSRIs and support the hypothesis that the mechanism of action of tianeptine relates to alteration of glutaminergic activity in the amygdala and the hippocampus. In addition to the above mechanisms, tianeptine is a unique antidepressant and anxiolytic medication that stimulates the uptake of serotonin (5-hydroxytryptamine; 5-HT), and 5-hydroxyindoleacetic acid (5-HIAA) in brain tissue. Although the monoaminergic neurotransmitters serotonin (5-HT), noradrenaline (NA) and dopamine (DA) are proven to be related to the occurrence of depressive disorders, it is now recognized that monoamine deficits are not sufficient to explain the mechanism of action of antidepressant medications.

PharmacodynamicsPH

Analyses in large-scale epidemiologic surveys have shown that the anxiety disorders are widely comorbid with major depression. This makes antidepressant with anxiolytic properties particularly unique and attractive. Tianeptine is effective in reducing depressive symptoms in mild to severe major depressive disorder and also alleviates anxious symptoms associated with depression without the need for coadministration of an anti-anxiety medication. These findings, however, are met with controversial data. In a study of healthy volunteers, Tianeptine-treated subjects were less accurate at identifying facial expressions, suggesting a lack of improvement in the psychomotor symptoms of depression. The tianeptine group also showed reduced memory and reduced attentional vigilance to various stimuli.

Pharmacokinetics

Half-lifePH

Approximately 2.5 h

AbsorptionPH

Well absorbed, approximately 99% bioavailability.
Eliminated with bile as glucuronide and glutamine conjugates.
0.8 L/kg (0.77 +/- 0.31 L/kg)
Rapidly cleared by the kidneys.

MetabolismPH

Tianeptine is metabolized primarily by beta-oxidation of its heptanoic side chain. The metabolism of tianeptine was studied after a one-time oral administration of radioisotopically (14C) labeled compound to healthy male volunteers. After 1 week, approximately 66% of the dose was eliminated by the kidneys (55% elimination during the first 24 hr). After 24h, unchanged drug 3% of the drug was found unchanged in the urine. Three major metabolites result from beta-oxidation of Tianeptine. The metabolite profiles of tianeptine in feces and plasma were found to be qualitatively similar to that in urine.

Protein bindingPH

95% bound to plasma protein.

Plan when to take Tianeptine — see where onset, peak and comedown land on the clock

Fact-sheets from PsychonautWiki. Harm-reduction reference only — not medical advice.